Enhancement of Antitumor Immunity by CTLA-4 Blockade

@article{Leach1996EnhancementOA,
  title={Enhancement of Antitumor Immunity by CTLA-4 Blockade},
  author={D. Leach and M. Krummel and J. Allison},
  journal={Science},
  year={1996},
  volume={271},
  pages={1734 - 1736}
}
  • D. Leach, M. Krummel, J. Allison
  • Published 1996
  • Biology, Medicine
  • Science
  • One reason for the poor immunogenicity of many tumors may be that they cannot provide signals for CD28-mediated costimulation necessary to fully activate T cells. [...] Key Result Here, in vivo administration of antibodies to CTLA-4 resulted in the rejection of tumors, including preestablished tumors. Furthermore, this rejection resulted in immunity to a secondary exposure to tumor cells. These results suggest that blockade of the inhibitory effects of CTLA-4 can allow for, and potentiate, effective immune…Expand Abstract

    Topics from this paper.

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    The proposed study will evaluate the safety and feasibility of neoadjuvant nivolumab +/- ipilimumab in resectable MPM. In addition, maintenance nivolumab will be administered for 1… Expand
    ConditionsMesothelioma
    InterventionDrug
    INTERVENTIONAL CLINICAL TRIAL
    The proposed study will evaluate the safety and feasibility of preoperative administration nivolumab +/- ipilimumab in patients with high-risk resectable NSCLC, and will facilitate a… Expand
    ConditionsNon-Small Cell Lung Cancer
    InterventionDrug
    Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals
    117

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 53 REFERENCES
    CTLA4 mediates antigen-specific apoptosis of human T cells.
    322